Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

Starting soon · Early Phase 1

Conditions studied: Systemic Sclerosis, Sclerodactyly

In brief

Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.

Key facts

Study ID

NCT07697274

Run by

Medical University of South Carolina

People needed

10

Starts

2026-09-01

Expected to finish

2027-11-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 and <60 years
• Diagnosis of systemic sclerosis
• Presence of sclerodactyly
• Ability to provide informed consent

You may not qualify if…

• Known hypersensitivity to hyaluronidase
• Pregnancy or breastfeeding
• Unstable systemic disease
• Recent changes in systemic immunomodulatory therapy
• Conditions interfering with safe digital injections

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.